MEDIVIR AB – YEAR-END REPORT JANUARY – DECEMBER 2021
Significant progress, both in the clinical program and in our business developmentOctober – December Financial summary for the quarter · Net turnover amounted to SEK 13.9 (1.5) million. · The loss before interest, tax, depreciation and amortization (EBITDA) amounted to SEK -23.5 (-10.6) million. Basic and diluted earnings per share amounted to SEK -0.44 (-0.46) and SEK -0.44 (-0.46) respectively. · Cash flow from operating activities amounted to SEK -5.4 (-1.0) million. · Liquid assets and short-term investments at the end of the period amounted to SEK 221.2 (70.0) million.